chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Starting mid-December 2022, developed sensation of skipped heart beats with pronounced thumping in chest after skipped beats. Pulse felt and confirmed missed beats. Intermittent but distracting. Not associated with any time of day or activity. Could occur at night/day/rest/exercise. With symptoms, felt like octopus was trying to escape my chest! Kardia mobile device confirmed PVCs (see also testing results) Symptoms persisted despite stopping alcohol intake Jan 13, 2023 - Feb 15, 2023. No change in caffeine intake (have been drinking 2-3 cups coffee daily for >20 years). Noted resolution of symptoms around Feb 27, 2023; confirmed weekly thereafter by lack of PVCs when checked on Kardia Mobile from March 1 - present
Persistent shoulder pain with weakness, persistent massage and physical therapy pending as of 4/29/2011
head ache, muscle ache, extreme tiredness, upset stomach for one 24 hour period. Tired and upset stomach the next 24 hour period, but able to go to work.
Mild Body aches and fatigue that lasted 18 hours.  Took Tylenol at 7:30 am  and ibuprofen at 11:40 am on 3/19/21. Better by mid afternoon  3/19/21.
Systemic: Fainting / Unresponsive-Mild, Systemic: Flushed / Sweating-Mild, Systemic: Shakiness-Mild, Additional Details: mother informed rph prior to shot that patient exhibits these reactions after receving shots. mother and rph held pt. he fell on his buttocks  but was unhurt while changing location. rph had advised mother to keep him sitted. we fanned him to cool his sweating. he drank 2boxes of juice. he left after 15minutes.
redness at the injection site; hives; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis.   On 17th August 2021, the patient received Boostrix (intramuscular) .5 ml. In August 2021, less than a week after receiving Boostrix, the patient experienced hives. On 18th August 2021, the patient experienced injection site erythema. The patient was treated with benadryl (nos) (Benadryl). On an unknown date, the outcome of the injection site erythema and hives were recovered/resolved.   It was unknown if the reporter considered the injection site erythema and hives to be related to Boostrix.  Additional details were provided as follows: The case was reported by the patient's friend. The age at vaccination was not reported. The reporter declined to provide demographic information and did not have many details. The patient received Boostrix on a Tuesday in unnown arm and next day after the vaccination patient had some redness at the injection site. On Friday or Saturday of the same week the patient had hives. The patient took Benadryl tablets and the hives resolved within days. The reporter did not consent to follow up.
Post vax, the pt developed a lemon-sized swelling in left thigh; did not seem to cause child pain. Advised ice and offered to see pt. Saw 9/15 am, at that time swelling at greatly reduced; advised to continue ice packs and use Benadryl.  Follow up 10/19/2000: "Not documented when reaction began."
Patient is a previously healthy 11 year old female who was admitted from the Emergency Center with a one day history of headache and altered mental status. Per mother, patient was in her usual state of health until yesterday 9/23/15. She received her Tdap and meningitis vaccines and almost immediately after receiving the meningitis vaccine she began to drop her head, feel weak, and was more tired. There was no immediate syncope. Mother next took her to school, however shortly after dropping her off patient experienced a syncopal episode in class. This was reportedly witnessed by a teacher and patient's sister. There was no reported head trauma with the syncope. Patient herself cannot recall the event. Mother then took patient to hospital where initial lab work included CBC, CMP, pregnancy test, and UDS were reportedly negative. Given her history of a new onset of light headache, a CT and MRI scan were performed, both of which were unremarkable. Patient was discharged home after receiving an unknown pain medication. On the way home, patient had her first "dazed" episode where mother states she would stare off into space. There was no deviation of her eyes, movements of her limbs, or loss of bowel/bladder control. Mother states that she could "snap her out of it" by snapping her fingers. The episodes would last approximately one minute and patient would return back to her baseline. Once home that same day, patient's headache continued to worsen and was located primarily behind her eyes. She denies any lacrimation or injection of her eyes. At approximately 20:30 on the evening prior to admission, patient was walking downstairs when mother noted her knees buckled but patient did not fall. At that moment, mother said patient walked from dark, to light, to dark and mother did not notice her pupils reacting the way they were supposed. This prompted mother to return to the ED at which point a physician reportedly also noted that the pupils were not reactive. The was not documented on review of the EC notes. Patient was then transferred to another EC for further evaluation. While en route, she was given IV ketorolac and a bolus of IV fluids which reportedly helped reduced her headache to a 2/10. At the EC, her physical exam was unremarkable. She was admitted for further evaluation and management of her headache and altered mental status spells.
On June 22, 2022 I had a bad sore throat, I felt achy all over. I used my home COVID19 test and it was negative. I took another test in the morning and it was negative. I went to the Health Department because I felt like I had a bad flu. In thirty-six hours the PCR COVID-19 test came back positive. I called my PCP and had a telehealth visit with the Physician Assistant, she prescribed the Paxlovid that I started taking as soon as I picked it up. After five days of taking the Paxlovid I fell better.
pt recv vax this AM, had fever, nausea, vomiting, h/a;tx APAP, DPH w/marked improvement;released to home;
Abnormal movement of left arm and head x 3 days prior to admission 5/4/14 (straightening (L) arm and turning head (L), episodes lasting seconds) about 30 episodes. Admitted 5/6/14, EEG did not show epileptiform activity.
Patient received COVID 19 vaccine the morning of 1/18/21 at Public Health COVID-19 vaccine clinic. I (person completing this report) work for PH. Later that night while in bed, patient reported difficulty breathing to his wife, then turned blue, and became unresponsive. Family report pt was without any symptoms prior to event.  911 called; CPR started by family member 15 min. after pt became unresponsive. EMS performed resuscitation for about 30-40 minutes with multiple defibrillation for V-fib.  Between EMS and Medical Center ER, pt had 9 rounds of epi, CPR w/ LUCAS  machine, given 2 doses of amiodarone (150 mg and 300 mg). Patient had 3 EKGs, which did not show STEMI, but did show nonspecific conduction delay and sinus arrest with junctional escape vs sinus bradycardia (HR 50's).  Pt had return of spontaneous circulation. Pt intubated, and started on Levophed. Pt transferred to ICU, and had central line placed.  Family decided to make patient DNR. Pt went into coarse VFib again, and as per wishes of family, code blue not called.  Patient expired at 01:53 on 1/19/21.
headache, bodyache, heart palpitations Narrative: Took Tylenol, Motrin, Zyrtec
98%, 83 pulse, 130/78, itching along L arm and leg, no rash, no sob, no diff swallowing, no allergies, heart WNL, lungs clear, drinking h20, observation-no rash, speaks full sentences, feeling a little better
Pt stated that on Thursday morning, she noticed her right arm was sore. Then, when she got home from work that night, she noticed her arm was sore, and starting to get red above the injection site. Then on Friday morning, she noticed her arm was also swollen, and seemed to be 'moving around her arm into her underarm area'.
Taste distortion (not able to eat beef/chicken/PB and other foods taste stale or have a metallic taste)
Pt presents with hives on left buttock area and back on 10/14/2021 after getting 2nd dose of Moderna Covid vaccine on 10/13/21. Took benadryl daily with no relief. Hives is itchy.  Referred to allergist for testing. Similar reaction with flu vaccine as per pt. Given hydroxyzine for itching, prednisone, and clobetasol.
Patient presented at the pharmacy with extensive bruising from mid arm to elbow.  She claimed that the pharmacist applied a tourniquet, which is why she was bruised.  I spoke with the pharmacist that administered the vaccination and confirmed that he did NOT use a tourniquet (we don't even have tourniquets).  The patient insisted that one was used, and I explained to her that we do not have, nor have ever had tourniquets.  I encouraged her to consult with her MD regarding the bruising, since something clearly had happened to cause it.  The shoulder area where the shot was administered was not bruised, so I suspect that something else caused it.  The patient was very elderly and not a reliable witness to ascertain what else could have happened.
Patient was given 12yrs> grey top instead of orange top 5yrs -11yrs. Patient did wait 15 min in office after vaccine and no reactions while in office. It is currently 3:42pm and parent has not called back to office reporting any adverse events.
This spontaneous report as received from a certified medical assistant refers to a patient of unknown demographics. On an unknown date, the patient was vaccinated with a dose of improperly stored GARDASIL (Lot number, expiry date, route and dose were not reported). The certified medical assistant reported that the vaccine was exposed to temperature of 26 F (Fahrenheit) for a total of 135 hours. No adverse effects reports. Follow-up received. Certified medical assistant stated other 104 children received GARDASIL. Follow up information has been received from the certified medical assistant regarding a 16 years old, male patient with no pertinent medical history reported. On 29-AUG-2012 the patient was vaccinated with the first dose of GARDASIL (lot number and expiration date not reported) (intramuscular on the right arm, dose not reported). On 14-NOV-2012 the patient received the second dose of GARDASIL (lot number and expiration date not reported) (intramuscular on the left arm, dose not reported). On 31-DEC-2012 the patient received the third dose of GARDASIL (lot number and expiration date not reported) (intramuscular on the right arm, dose not reported). It was reported that the patient did not seek medical attention. This is one of the several reports from the same source. Additional information is not expected.
injection site is red, warm, swollen, and sore; injection site is red, warm, swollen, and sore; injection site is red, warm, swollen, and sore; injection site is red, warm, swollen, and sore; left arm was in severe pain; This is a spontaneous report from a contactable consumer or other non hcp. A 51 year old female patient received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration, administered in Arm Left on 25Jun2021 16:00 (Batch/Lot Number: EL00217) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included autoimmune Hashimoto's  thyroiditis from an unknown date and unknown if ongoing for past 5.5 years , infectious mononucleosis from an unknown date and unknown if ongoing for past 5.5 years. Concomitant medication(s) included levothyroxine (LEVOTHYROXINE) taken for an unspecified indication, start and stop date were not reported; creatine (CREATINE) taken for an unspecified indication, start and stop date were not reported; vitamin b complex (B COMPLEX (B50)) taken for an unspecified indication, start and stop date were not reported; colecalciferol (D3) taken for an unspecified indication, start and stop date were not reported.  The patient previously took Depakote and imipramine and experienced drug hypersensitivity. From about 8 hours after the shot until about 44 hours later, the patient experienced left arm severe pain on 26Jun2021 with outcome of recovered. Also had injection site redness, warmth, swollen, and sore on 02Jul2021 04:00 with outcome of not recovered.   Follow-up (06Jul2021): Follow-up attempts are completed. No further information is expected.
Tested positive for COVID; Tested positive for COVID; flu like symptoms; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A male patient in his 40's received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Tested positive for COVID"; INFLUENZA LIKE ILLNESS (non-serious), outcome "unknown", described as "flu like symptoms". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Clinical Course: It was reported that her husband, withheld, mid 40s also tested positive for COVID. Both have flu like symptoms.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202200025192 same reporter/ drug/ event, different patient;
This spontaneous report was received from a consumer and refers to his mother, a female patient of unknown age. There was no information about patient's pertinent medical history, drug reactions or allergies provided. On 15-AUG-2015, the patient was vaccinated with ZOSTAVAX (lot#, expiration date, dose, site and route of administration were not reported), PNEUMOVAX 23 (lot#, expiration date, dose, site and route of administration were not reported) and influenza virus vaccine (unspecified). On unknown date in August 2015, the patient experienced a "bad headache" and probably took MOTRIN as home treatment. The outcome of the event was unknown. The relatedness between the event and ZOSTAVAX, PNEUMOVAX 23, influenza virus vaccine (unspecified) was not reported. This is one of several reports received from the same reporter. Additional information has been requested.
Injection site became swollen to 2x normal size, hot, red, hard. Took a long time to go away.
Age discrepancy - vaccine given despite age under 18 by accident.  No adverse events reported
Later that day vomited, fever, lasted a day or two.  Pain in arm so bad I could not move my arm for two or three days.  Fasciculations all over my body, any time I was at rest, began about two weeks after second dose (mid-March).  After about three months they started to abate.  They still occur in my feet and lower legs but they are much milder.
10 minutes after vaccine, employee developed tightness in throat and all over: "feels like swelling"; coloration very red. BP-183/95, P-88, R-20. Treatment 25mg IV Benadryl. Feeling better within 5 minutes with normal color, BP-157/95, P-81. Tightness subsiding 20 minutes and symptoms gone.
his knuckles hurt; a fast heartbeat; chills; headache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received bnt162b2 (COMIRNATY), administration date 29Sep2021 (Batch/Lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "COVID-19", start date: Nov2020 (unspecified if ongoing), notes: he tested positive for COVID-19 in November where he got tested for work. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1), administration date: 21Dec2020, for Covid-19 Immunization, reaction(s): "his shoulder was sore"; Bnt162b2 (DOSE 2), administration date: 08Jan2021, for Covid-19 Immunization, reaction(s): "his shoulder was very sore".  The following information was reported: ARTHRALGIA (non-serious) with onset Sep2021, outcome "unknown", described as "his knuckles hurt"; HEART RATE INCREASED (non-serious) with onset Sep2021, outcome "unknown", described as "a fast heartbeat"; CHILLS (non-serious) with onset Sep2021, outcome "unknown", described as "chills"; HEADACHE (non-serious) with onset Sep2021, outcome "unknown", described as "headache". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Caller stated that he received his first dose of the Pfizer COVID-19 vaccine last 21Dec2020 where "his shoulder was sore". Caller received his second dose of the vaccine last 08Jan2021 and mentioned that "the nurse injected it in his shoulder IM and that his shoulder was very sore and needed ice to relieve it". Caller received his booster dose of the Pfizer COVID-19 vaccine last 29Sep2021 "first thing in the morning and he felt good, but late night to early morning at around 1 or 3 or 4 am, his knuckles hurt, he had a fast heartbeat, had chills, had headache and it hit him harder than the actual COVID as he tested positive for COVID-19 in November where he got tested for work". Caller wanted to know why he sad such an effect with the booster dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
56 adults patients received doses after its expiration date Jul 13, 2022; no adverse event; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (56 adults patients received doses after its expiration date Jul 13, 2022) and NO ADVERSE EVENT (no adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. 004m21) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (56 adults patients received doses after its expiration date Jul 13, 2022) and NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (56 adults patients received doses after its expiration date Jul 13, 2022) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (56 adults patients received doses after its expiration date Jul 13, 2022).    No concomitant medications were reported. It was unknown whether patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. Caller mentioned that "the CDC had just approved extended expiration dates" and wanted to know if it was extended. When asked the caller stated that there were no remaining vials unused of that lot number and the agent reminded the caller that no patients should receive doses from expired vials. Dose was administered after 30-day Use by Date or after manufacturer date of expiry. Vial did not undergo any temperature excursions.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-701125 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-701125:Master case
Mother called AM of 09/18/2009 to report baby was having reaction to vaccines. States she cried all night - only sleeping in 15 min episodes - feels warm to touch. Giving TYLENOL - no problem w/eating or drinking. PHN called mother in PM to check on child. Not really crying - but "pouting" - still hasn't checked temp - "feels warm" - wants to be held. No pediatrician yet - inst alternate TYLENOL w/MOTRIN to equal total of 4 doses/24 hours. PHN called Back 09/21/09 - child doing well - all shot sites warm to touch & red.
NauseaVomiting History of vasovagal episodes; c/o warm feeling and nausea without vomiting. Recovered Narrative: 10 minutes after vaccine admin. c/o/ warmth and nausea. Triaged by the ER nurse and observed for 45 minutes. Discharged in stable condition 133/84, 104, 18
Patient was accidently given 2 doses of HPV vaccine instead of 1 , patient experienced no symptoms after injections while in office.
This spontaneous report as received from a pharmacist refers to a patient of unknown age and gender. The patient completed the primary 3 doses of Hepatitis B vaccination series sometime between 1995 and 1999 (manufacturer unspecified, but RECOMBIVAX HB (Merck) could not be ruled out at the time of the call) and recently had a negative titer for Hepatitis B. No adverse event other than the negative Hepatitis B titer. Additional information is not expected.
facial dermatits extending from infraorbital region bilat to the sides of nose-cheeks, anterior neck region, began PM on date of vax;
Miscarriage. Bleeding started on 10/19/19 and tissue was passed 10/20/19.  EDD: 5/17/19, no previous pregnancy complications.
This case was reported by a physician via call center representative and described the occurrence of chills in a 56-year-old female patient who received SHINGRIX (batch number YS53Y, expiry date 30th January 2020) for prophylaxis. On 4th June 2018, the patient received the 1st dose of SHINGRIX (intramuscular). In June 2018, 9 days after receiving SHINGRIX, the patient experienced chills (serious criteria disability), nausea (serious criteria disability), myalgia (serious criteria disability), malaise (serious criteria disability), fever (serious criteria disability) and shaking (serious criteria disability). In June 2018, the outcome of the chills, myalgia, malaise and shaking were recovered/resolved. On an unknown date, the outcome of the nausea was not recovered/not resolved and the outcome of the fever was unknown. It was unknown if the reporter considered the chills, nausea, myalgia, malaise, fever and shaking to be related to SHINGRIX. Additional information was received as follows: The patient developed a sudden onset of events. In June 2018, the patient's body temperature was recorded as 102.5 degree F. The healthcare professional stated that the fever was disabling for the patient (because it was 102.5 F). Also, the patient went to the emergency room and then also went to the physician's office.
few minutes after vaccine-developed hives torso, extremities, and face. Symptoms or facial mouth lip swelling. Benadryl given-observed > 1 hours. Then discharge home with follow call done.
This case was reported by a consumer via call center representative and described the occurrence of vertigo in a patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a week after receiving SHINGRIX, the patient experienced vertigo and inability to work. On an unknown date, the outcome of the vertigo and inability to work were unknown. It was unknown if the reporter considered the vertigo and inability to work to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient spent two days (day 2 and 3 following injection) physically unable to do anything but cautiously move to bathroom with debilitating vertigo.